Living systematic reviews
.
..
Other useful information:
- https://www.cochrane.org/coronavirus-covid-19-cochrane-resources-and-news
- http://www.transfusionevidencelibrary.com/
- Our reviews regarding blood transfusion:
- A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
- Alternative agents to prophylactic platelet transfusion for preventing bleeding in people with thrombocytopenia due to chronic bone marrow failure: a meta-analysis and systematic review.
- Alternatives, and adjuncts, to prophylactic platelet transfusion for people with haematological malignancies undergoing intensive chemotherapy or stem cell transplantation.
- Antifibrinolytics (lysine analogues) for the prevention of bleeding in people with haematological disorders.
- Comparison of a restrictive versus liberal red cell transfusion policy for patients with myelodysplasia, aplastic anaemia, and other congenital bone marrow failure disorders.
- Comparison of a therapeutic-only versus prophylactic platelet transfusion policy for people with congenital or acquired bone marrow failure disorders.
- Comparison of different platelet count thresholds to guide administration of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
- Comparison of different platelet transfusion thresholds prior to insertion of central lines in patients with thrombocytopenia.
- Different doses of prophylactic platelet transfusion for preventing bleeding in people with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation.
- Disease-modifying treatments for primary autoimmune haemolytic anaemia.
- Erythropoietin or Darbepoetin for patients with cancer - meta-analysis based on individual patient data.
- Erythropoietin or darbepoetin for patients with cancer.
- Intravenous iron versus oral iron versus no iron with or without erythropoiesis- stimulating agents (ESA) for cancer patients with anaemia: A systematic review and network meta-analysis.
- Pathogen-reduced platelets for the prevention of bleeding.
- Plasma transfusions prior to insertion of central lines for people with abnormal coagulation.
- Plasma transfusions prior to lumbar punctures and epidural catheters for people with abnormal coagulation.
- Prophylactic plasma transfusion for patients without inherited bleeding disorders or anticoagulant use undergoing non-cardiac surgery or invasive procedures.
- Prophylactic platelet transfusions prior to surgery for people with a low platelet count.
- Restrictive versus liberal red blood cell transfusion strategies for people with haematological malignancies treated with intensive chemotherapy or radiotherapy, or both, with or without haematopoietic stem cell support.
- TPO receptor agonist for chronic idiopathic thrombocytopenic purpura
- The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents
- Thrombopoietin mimetics for patients with myelodysplastic syndromes
- Thrombopoietin receptor agonists for prevention and treatment of chemotherapy-induced thrombocytopenia in patients with solid tumours.
- Treatment for disseminated intravascular coagulation in patients with acute and chronic leukemia.
- Use of platelet transfusions prior to lumbar punctures or epidural anaesthesia for the prevention of complications in people with thrombocytopenia.